نتائج البحث - "Audrey Rabeau"

1

Pediatrician intervention impacts parental smoking in cystic fibrosis, diabetes, and bronchiolitis

المؤلفون: Geraldine Labouret, Marine Michelet, M. Mittaine, Amélie Arrouy, Carole Morin, Léa Roditis, Maxime Lafont, Audrey Rabeau

المصدر: Pediatric Pulmonology. 56:1716-1723

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d3f783340a78c0ac76b29d3501c79b2Test
https://doi.org/10.1002/ppul.25277Test

2

Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors

المساهمون: Pulmonologie, Promovendi ODB, MUMC+: MA Med Staf Spec Longziekten (9), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Radiotherapie

المصدر: Journal of Thoracic Oncology, 14(7), 1244-1254. Elsevier Science

مصطلحات موضوعية: 0301 basic medicine, Male, Lung Neoplasms, Programmed Cell Death 1 Receptor, Pembrolizumab, NSCLC, Gastroenterology, B7-H1 Antigen, 0302 clinical medicine, Antineoplastic Agents, Immunological, Disease specific Graded Prognostic Assessment, Carcinoma, Non-Small-Cell Lung, Checkpoint inhibition, Medicine, Aged, 80 and over, DOCETAXEL, Brain Neoplasms, Middle Aged, Prognosis, OPEN-LABEL, Survival Rate, Oncology, Docetaxel, 030220 oncology & carcinogenesis, Cohort, Carcinoma, Squamous Cell, Female, Nivolumab, medicine.drug, Pulmonary and Respiratory Medicine, Adult, medicine.medical_specialty, Adenocarcinoma of Lung, survival, 03 medical and health sciences, Internal medicine, PATIENTS PTS, Humans, Lung cancer, PEMBROLIZUMAB, Pseudoprogression, Aged, Retrospective Studies, business.industry, Proportional hazards model, NIVOLUMAB, Brain metastases, medicine.disease, EFFICACY, Confidence interval, LIFE, 030104 developmental biology, business, SYSTEM, Follow-Up Studies

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f71577960fdcb3b6db9e0ec054f54aa9Test
https://doi.org/10.1016/j.jtho.2019.02.009Test

3

A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial

المساهمون: Equipe Quantification en Imagerie Fonctionnelle (QuantIF-LITIS), Laboratoire d'Informatique, de Traitement de l'Information et des Systèmes (LITIS), Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Université Le Havre Normandie (ULH), Normandie Université (NU)-Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), Normandie Université (NU)

المصدر: Journal of Thoracic Oncology
Journal of Thoracic Oncology, Lippincott, Williams & Wilkins, 2019, 14 (5), pp.903-913. ⟨10.1016/j.jtho.2019.01.008⟩

مصطلحات موضوعية: Male, 0301 basic medicine, Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, Lung Neoplasms, Randomization, [SDV]Life Sciences [q-bio], medicine.medical_treatment, Phases of clinical research, Antineoplastic Agents, Antibodies, Monoclonal, Humanized, 03 medical and health sciences, 0302 clinical medicine, Atezolizumab, Internal medicine, medicine, Clinical endpoint, Chemotherapy, Humans, Aged, Aged, 80 and over, Programmed cell death ligand 1, business.industry, SCLC, Middle Aged, Small Cell Lung Carcinoma, Confidence interval, 3. Good health, 030104 developmental biology, 030220 oncology & carcinogenesis, Toxicity, Female, Topotecan, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0f0c334a072ea9fa844d16554706157Test
https://doi.org/10.1016/j.jtho.2019.01.008Test

4

Granulomatose sarcoïdosique survenant sous inhibiteurs de point de contrôle immunitaire

المؤلفون: Julien Mazieres, Isabelle Rouquette, C. Goumarre, G. Faviez, Audrey Rabeau, Samia Collot, Nicolas Meyer, E. Bousquet, G. Prévot

المصدر: Revue des Maladies Respiratoires. 35:963-967

مصطلحات موضوعية: Pulmonary and Respiratory Medicine, Gynecology, 03 medical and health sciences, medicine.medical_specialty, 0302 clinical medicine, business.industry, Antibodies monoclonal, 030220 oncology & carcinogenesis, medicine, 030212 general & internal medicine, business, Programmed Cell Death 1 Receptor

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::1194ce8aaac27d191c0149f8a82367b3Test
https://doi.org/10.1016/j.rmr.2018.08.003Test

5

Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: preliminary results from the real-world EVIDENS study

المصدر: Oncoimmunology
article-version (VoR) Version of Record
OncoImmunology, Vol 9, Iss 1 (2020)

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b3aa8e4cd6d1d9936466474b2b2ea83Test
https://pubmed.ncbi.nlm.nih.gov/33457089Test

6

Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab

المساهمون: Centre hospitalier universitaire de Nantes (CHU Nantes), Intergroupe Francophone de Cancérologie Thoracique [Paris] (IFCT), Intergroupe Francophone de Cancérologie thoracique, Assistance Publique - Hôpitaux de Marseille (APHM), Centre Hospitalier Intercommunal Toulon-La Seyne sur Mer - Hôpital Sainte-Musse, Institut de Cancérologie de Lorraine - Alexis Vautrin [Nancy] (UNICANCER/ICL), UNICANCER, Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), CHU Grenoble, Service de pneumologie, oncologie thoracique et soins intensifs respiratoires [Rouen], Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Hôpital Charles Nicolle [Rouen]-CHU Rouen, Normandie Université (NU), Hôpital Bretonneau, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Service de pneumologie [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] (UNICANCER/CAL), UNICANCER-Université Côte d'Azur (UCA), Service de pneumologie [Centre Hospitalier Lyon Sud - HCL], Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Service d’oncologie thoracique et essais précoces [CHU Bichat], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Clermont-Ferrand, Centre Hospitalier Le Mans (CH Le Mans), Centre hospitalier de Pau, Service de pneumologie [Toulouse], CHU Toulouse [Toulouse]-Hôpital Larrey [Toulouse], CHU Toulouse [Toulouse], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Hôpital Charles Nicolle [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Herrada, Anthony, Hôpital Charles Nicolle [Rouen]-CHU Rouen

المصدر: Journal of Clinical Medicine
Journal of Clinical Medicine, MDPI, 2020, 9 (12), pp.3861. ⟨10.3390/jcm9123861⟩
Journal of Clinical Medicine, Vol 9, Iss 3861, p 3861 (2020)
Journal of Clinical Medicine, 2020, 9 (12), pp.3861. ⟨10.3390/jcm9123861⟩
Volume 9
Issue 12

مصطلحات موضوعية: Oncology, atezolizumab, medicine.medical_specialty, medicine.medical_treatment, lcsh:Medicine, [SDV.CAN]Life Sciences [q-bio]/Cancer, medicine.disease_cause, Article, 03 medical and health sciences, 0302 clinical medicine, Germline mutation, [SDV.CAN] Life Sciences [q-bio]/Cancer, Atezolizumab, Internal medicine, medicine, RB1, Progression-free survival, TP53, 030304 developmental biology, 0303 health sciences, Chemotherapy, Mutation, business.industry, lcsh:R, SCLC, General Medicine, Immunotherapy, [SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/Immunotherapy, ctDNA, NOTCH, 3. Good health, Clinical trial, 030220 oncology & carcinogenesis, Non small cell, [SDV.IMM.IMM] Life Sciences [q-bio]/Immunology/Immunotherapy, mutation, business